Marbofloxacin-d8 is intended for use as an internal standard for the quantification of marbofloxacin by GC- or LC-MS. Marbofloxacin is a fluoroquinolone antibiotic that is active against P. multocida in vitro (MIC = 0.016 μg/ml).1 It exhibits broad-spectrum antibacterial activity mediated by the inhibition of DNA gyrase, with MIC values ranging from 0.016 to 0.4 and 0.19 to 1.7 µg/ml against various Gram-negative and Gram-positive bacterial isolates, respectively.2 Intramuscular administration of marbofloxacin (2 mg/kg) after infection prevents the formation of pulmonary lesions in a bovine calf model of M. haemolytica A1 pneumonia.3 Oral administration of marbofloxacin (2 mg/kg per day) also exhibits antileishmanial activity in a canine model of leishmaniasis, decreasing parasitic load by 72%.4 Formulations containing marbofloxacin have been used in the veterinary treatment of bacterial infections.
1.Ferran, A.A., Toutain, P.L., and Bousquet-MÉlou, A.Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infectionVet. Microbiol.148(2-4)292-297(2011) 2.Spreng, M., Deleforge, J., Thomas, V., et al.Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolatesJ. Vet. Pharmacol. Ther.18(4)284-289(1995) 3.Lhermie, G., Ferran, A.A., AssiÉ, S., et al.Impact of timing and dosage of a fluoroquinolone treatment on the microbiological, pathological, and clinical outcomes of calves challenged with Mannheimia haemolyticaFront. Microbiol.237(7)(2016) 4.Pineda, C., Aguilera-Tejero, E., Morales, M.C., et al.Treatment of canine leishmaniasis with marbofloxacin in dogs with renal diseasePLoS One12(10)e0185981(2017)